innovation

Europe's IMI Sets Pace for Public/Private Partnerships in Pharmaceutical Development

A recent PharmaTimes article highlighted the efforts of the largest public/private partnership in the pharmaceutical industry, Europe’s Innovative Medicines Initiative (IMI).  The IMI, jointly funded for 2 billion euros by the European Commission and the industry group, the European Federation of Pharmaceutical Industries and Associations (EFPIA), seeks to address the development and delivery issues for …

Europe's IMI Sets Pace for Public/Private Partnerships in Pharmaceutical Development Read More »

The Trifecta of Mutually-Beneficial Relationships: KOLs, Pharma and Patients—Part Two

KOLs Provide the “Voice of the Patient” for Life-changing Discoveries According to the Pharmaceutical Research and Manufacturers of America (PhRMA—(http://www.phrma.org/), “Only one of every 10,000 potential medicines investigated by America’s research-based pharmaceutical companies makes it through the research and development pipeline and is approved for patient use by the United States Food and Drug Administration.” …

The Trifecta of Mutually-Beneficial Relationships: KOLs, Pharma and Patients—Part Two Read More »